{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:48:58Z","timestamp":1789501738886,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Adjuvant anti-PD-1 therapy improves recurrence-free survival (RFS) in high-risk melanoma, but many patients experience adverse events. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography [18F]FDG-PET\/CT has been proposed to identify biomarkers that may predict outcome of treatment. Objectives: The aim of this register-based study was to investigate the prognostic value of immune-related adverse events (irAEs), spleen-to-liver ratio (SLR), and bone marrow-to-liver ratio (BLR), detected by [18F]FDG-PET\/CT. Methods: This retrospective, register-based cohort study included 122 patients with radically resected stage III\u2013IV melanoma treated with adjuvant anti-PD-1. Patient data were extracted from a Danish register, and measurements for SLR and BLR were made using an AI model. Cox regression models were made on irAEs and BLR to assess associations with RFS and overall survival (OS). Results: Over half of the patients experienced recurrence, and one quarter died during follow-up of 4 \u00be years. Seventy-four percent exhibited at least one PET-detected irAE. This study found no association between irAEs and OS. Regarding RFS, our findings suggest an increased risk of recurrence for the presence of irAEs within the first 1.5 years of follow-up (HR: 2.93, CI: 1.10\u20137.84, p = 0.032). BLR and SLR were not associated with RFS or OS in multivariable models. Conclusions: This study did not confirm the findings of a positive association between irAEs and survival found in previous studies. PET-detected irAEs were common in the study population, but did not predict OS, while early-onset irAEs were linked to increased recurrence risk. Neither SLR nor BLR demonstrated prognostic value. Further research is needed to clarify the clinical utility of PET-derived biomarkers, especially in the adjuvant setting.<\/jats:p>","DOI":"10.3390\/diagnostics16010079","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T03:06:02Z","timestamp":1766718362000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Prognostic Value of Biomarkers Identified by [18F]FDG-PET\/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4203-1654","authenticated-orcid":false,"given":"Anne-Line Mayland","family":"Madsen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6335-3303","authenticated-orcid":false,"given":"Oke","family":"Gerke","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark"},{"name":"Department of Oncology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2720-9018","authenticated-orcid":false,"given":"Malene Grubbe","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambavy","family":"Nadaraja","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): Distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"EVIDoa2200214","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/oncolo\/oyac266","article-title":"Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy","volume":"28","author":"Atkinson","year":"2023","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00262-022-03302-5","article-title":"Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: A propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival","volume":"72","author":"Weber","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","article-title":"The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: A systematic review and meta-analysis","volume":"48","author":"Ayati","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","unstructured":"Elleb\u00e6k, E. (2021). Adjuverende Behandling af Melanom, Dansk Melanom Gruppe. [1st ed.]."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00259-020-05103-3","article-title":"Assessing immune organs on 18F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: Inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients","volume":"48","author":"Prigent","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2967\/jnumed.120.254482","article-title":"Prognostic Value of Bone Marrow Metabolism on Pretreatment (18)F-FDG PET\/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy","volume":"62","author":"Nakamoto","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00259-023-06243-y","article-title":"The prognostic value of [18F]FDG PET\/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: Comparison of different metabolic criteria","volume":"50","author":"Sachpekidis","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1007\/s00259-023-06327-9","article-title":"Can physiologic colonic [18F]FDG uptake in PET\/CT imaging predict response to immunotherapy in metastatic melanoma?","volume":"50","author":"Sachpekidis","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13550-021-00832-4","article-title":"Assessment of early metabolic progression in melanoma patients under immunotherapy: An 18F-FDG PET\/CT study","volume":"11","author":"Sachpekidis","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","article-title":"Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4","volume":"47","author":"Seban","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: Association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","article-title":"18F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma","volume":"20","author":"Wong","year":"2020","journal-title":"Cancer Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"Kim","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/imt-2018-0146","article-title":"Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients","volume":"11","author":"Lang","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","article-title":"The Advantages and Challenges of Using FDG PET\/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy","volume":"44","author":"Wong","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","article-title":"FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment","volume":"47","author":"Iravani","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s11604-024-01554-y","article-title":"Organ-specific accuracy of [18F]FDG-PET\/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor","volume":"42","author":"Gideonse","year":"2024","journal-title":"Jpn. J. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","article-title":"Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET\/CT","volume":"44","author":"Nobashi","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1007\/s00259-022-05788-8","article-title":"Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer","volume":"49","author":"Humbert","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CMR.0000000000000541","article-title":"18F-FDG PET\/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab","volume":"29","author":"Sachpekidis","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s00259-022-05704-0","article-title":"The diagnostic accuracy and clinical impact of FDG-PET\/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma","volume":"49","author":"Andersen","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101943","DOI":"10.1016\/j.canep.2021.101943","article-title":"The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients","volume":"73","author":"Ellebaek","year":"2021","journal-title":"Cancer Epidemiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40658-020-00316-9","article-title":"RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology","volume":"7","author":"Borrelli","year":"2020","journal-title":"EJNMMI Phys."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Edenbrandt, L., Enqvist, O., Larsson, M., and Ul\u00e9n, J. (2022). Organ Finder\u2014A new AI-based organ segmentation tool for CT. medRxiv.","DOI":"10.1101\/2022.11.15.22282357"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1038\/s41598-021-89656-9","article-title":"Artificial intelligence could alert for focal skeleton\/bone marrow uptake in Hodgkin\u2019s lymphoma patients staged with FDG-PET\/CT","volume":"11","author":"Sadik","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1198\/000313005X70371","article-title":"Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator","volume":"59","author":"Snapinn","year":"2005","journal-title":"Am. Stat."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kleinbaum, D.G., and Klein, M. (2012). Survival Analysis: A Self-Learning Text, Springer. [3rd ed.].","DOI":"10.1007\/978-1-4419-6646-9"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-016-1953-z","article-title":"Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients","volume":"66","author":"Jordan","year":"2017","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/1\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T03:18:34Z","timestamp":1766719114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/1\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diagnostics16010079"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16010079","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}